NCT06617169 - Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions

Solid Tumor, AdultBladder CancerUrothelial CarcinomaTriple-negative Breast CancerLung CancerColorectal CancerGastric CancerOvarian CancerPancreatic Cancer

Interventions

DRUG

MNPR-101-PCTA-177Lu

MNPR-101-PCTA-177Lu administered intravenously over approximately 20 minutes, followed by a normal saline flush. Dosing will occur on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.

Trial Locations (1)

3051

RECRUITING

Melbourne Theranostic Innovation Centre (MTIC), North Melbourne